<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-042042</identifier>
<setSpec>1139-9287</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">MDMA and serotonin: based on two cases</dc:title>
<dc:description xml:lang="en">3,4-methylenedioxyamphetamine (MDMA) or «ecstasy » damages serotonin neurons in all animal species and there is growing evidence that this finding also applies to humans.This fact, together with the increasing extended use in the young population, has important repercussions in the appearance of specific psychopathologic and cognitive disturbances associated to its use.The authors present two clinical cases, in which psychopathological and cognitive symptoms are detected in MDMA users that support this hypothesis. Problems in the diagnosis of psychiatric disorders associated to MDMA and its clinical and therapeutic implications are discussed (AU)</dc:description>
<dc:creator>García Cabez, I</dc:creator>
<dc:creator>Zabal, A</dc:creator>
<dc:creator>Soto-Montenegro, ML</dc:creator>
<dc:creator>Arango, C</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La 3,4-metilenodioximetanfetamina (MDMA) o «éxtasis» produce lesiones en neuronas serotoninérgicas en todas las especies animales y cada vez existen más evidencias de que estos hallazgos pueden ser extrapolados a humanos.Este hecho, junto con su uso cada vez más extendido en la población joven, tiene importantes repercusiones en la aparición de determinados trastornos psicopatólogicos y alteraciones cognitivas asociados a su consumo.Los autores presentan dos casos donde se detectan síntomas psicóticos y neurocognitivos en consumidores de MDMA que apoyan esta hipótesis y discuten las dificultades diagnósticas relacionadas con los tratornos psiquiátricos asociados al consumo de drogas, así como sus implicaciones clínicas y terapéuticas (AU)</dc:description>
<dc:source>Actas Esp Psiquiatr;33(5): 339-342, sept.-oct. 2005.</dc:source>
<dc:identifier>ibc-042042</dc:identifier>
<dc:title xml:lang="es">MDMA y serotonina: a propósito de dos casos</dc:title>
<dc:subject>^d29622</dc:subject>
<dc:subject>^d33537^s22012</dc:subject>
<dc:subject>^d29315</dc:subject>
<dc:subject>^d24311^s22044</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d14065^s22044</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d14065^s22021</dc:subject>
<dc:subject>^d12041^s22027</dc:subject>
<dc:subject>^d6366^s22020</dc:subject>
<dc:subject>^d12041^s22044</dc:subject>
<dc:subject>^d32121^s22020</dc:subject>
<dc:type>article</dc:type>
<dc:date>200509</dc:date>
</metadata>
</record>
</ibecs-document>
